Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tyrosine kinase inhibitor dose reduction during the management of accelerated phase chronic myeloid leukemia.
Ortí G, García-Gutiérrez V, Bautista G, Ferrer-Marín F, Vallansot R, Xicoy B, Sánchez À, Simon I, Triguero A, Sierra M, Casado LF; Grupo Español de Leucemia Mieloide Crónica (GELMC). Ortí G, et al. Among authors: xicoy b. Leuk Res. 2022 Oct;121:106923. doi: 10.1016/j.leukres.2022.106923. Epub 2022 Aug 4. Leuk Res. 2022. PMID: 35933910 No abstract available.
Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
Marcé S, Zamora L, Cabezón M, Xicoy B, Boqué C, Fernández C, Grau J, Navarro JT, Fernández de Sevilla A, Ribera JM, Feliu E, Millá F; Grupo ICO de estudio de mutaciones de ABL en pacientes afectos de LMC. Marcé S, et al. Among authors: xicoy b. Med Clin (Barc). 2013 Aug 4;141(3):95-9. doi: 10.1016/j.medcli.2012.10.028. Epub 2013 Feb 22. Med Clin (Barc). 2013. PMID: 23433665
Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
Alvarez-Larrán A, Martínez-Avilés L, Hernández-Boluda JC, Ferrer-Marín F, Antelo ML, Burgaleta C, Mata MI, Xicoy B, Martínez-Trillos A, Gómez-Casares MT, Durán MA, Marcote B, Ancochea A, Senín A, Angona A, Gómez M, Vicente V, Cervantes F, Bellosillo B, Besses C. Alvarez-Larrán A, et al. Among authors: xicoy b. Ann Hematol. 2014 Dec;93(12):2037-43. doi: 10.1007/s00277-014-2152-7. Epub 2014 Jul 2. Ann Hematol. 2014. PMID: 24981691 Clinical Trial.
Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry.
Bernal T, Martínez-Camblor P, Sánchez-García J, de Paz R, Luño E, Nomdedeu B, Ardanaz MT, Pedro C, Amigo ML, Xicoy B, del Cañizo C, Tormo M, Bargay J, Valcárcel D, Brunet S, Benlloch L, Sanz G; Spanish Group on Myelodysplastic Syndromes; PETHEMA Foundation; Spanish Society of Hematology. Bernal T, et al. Among authors: xicoy b. Leukemia. 2015 Sep;29(9):1875-81. doi: 10.1038/leu.2015.115. Epub 2015 May 6. Leukemia. 2015. PMID: 25943181 Free article.
Long-term results of prednisone treatment for the anemia of myelofibrosis.
Hernández-Boluda JC, Martínez-Trillos A, García-Gutiérrez V, Ferrer-Marín F, Xicoy B, Alvarez-Larrán A, Kerguelen A, Barba P, Gómez M, Herrera JC, Correa JG, Cervantes F. Hernández-Boluda JC, et al. Among authors: xicoy b. Leuk Lymphoma. 2016;57(1):120-4. doi: 10.3109/10428194.2015.1046866. Epub 2015 Jun 18. Leuk Lymphoma. 2016. PMID: 25944376
Comparison of three prognostic scoring systems in a series of 146 cases of chronic myelomonocytic leukemia (CMML): MD Anderson prognostic score (MDAPS), CMML-specific prognostic scoring system (CPSS) and Mayo prognostic model. A detailed review of prognostic factors in CMML.
Calvo X, Nomdedeu M, Santacruz R, Martínez N, Costa D, Pereira A, Estrada N, Xicoy B, Esteve J, Nomdedeu B. Calvo X, et al. Among authors: xicoy b. Leuk Res. 2015 Jul 23:S0145-2126(15)30324-6. doi: 10.1016/j.leukres.2015.05.017. Online ahead of print. Leuk Res. 2015. PMID: 26354683
The division of chronic myelomonocytic leukemia (CMML)-1 into CMML-0 and CMML-1 according to 2016 World Health Organization (WHO) classification has no impact in outcome in a large series of patients from the Spanish group of MDS.
Xicoy B, Triguero A, Such E, García O, Jiménez MJ, Arnán M, Bernal T, Diaz-Beya M, Valcárcel D, Pedro C, Ramos F, Amigo ML, Collado R, Palomo L, Ardanaz MT, Cedena MT, Grau J, Zamora L, Sanz G. Xicoy B, et al. Leuk Res. 2018 Jul;70:34-36. doi: 10.1016/j.leukres.2018.05.003. Epub 2018 May 9. Leuk Res. 2018. PMID: 29775844 No abstract available.
Immediate Effects of Dasatinib on the Migration and Redistribution of Naïve and Memory Lymphocytes Associated With Lymphocytosis in Chronic Myeloid Leukemia Patients.
Colom-Fernández B, Kreutzman A, Marcos-Jiménez A, García-Gutiérrez V, Cuesta-Mateos C, Portero-Sainz I, Pérez-García Y, Casado LF, Sánchez-Guijo F, Martínez-López J, Ayala RM, Boqué C, Xicoy B, Montero I, Soto C, Paz R, Silva G, Vega-Piris L, Steegmann JL, Muñoz-Calleja C. Colom-Fernández B, et al. Among authors: xicoy b. Front Pharmacol. 2019 Nov 25;10:1340. doi: 10.3389/fphar.2019.01340. eCollection 2019. Front Pharmacol. 2019. PMID: 31824308 Free PMC article.
151 results